Genetic variants associated with phenytoin-related severe cutaneous adverse reactions

JAMA

Volumn 312, Issue 5, 2014, Pages 525-535

  Chung, Wen Hung ^a,b   Chang, Wan Chun ^c   Lee, Yun Shien ^d   Wu, Ying Ying ^c   Yang, Chih Hsun ^a,b   Ho, Hsin Chun ^a,b   Chen, Ming Jing ^a,b   Lin, Jing Yi ^a,b   Hui, Rosaline Chung Yee ^a,b   Ho, Ji Chen ^a,b   Wu, Wei Ming ^a,b   Chen, Ting Jui ^c,e   Wu, Tony ^a,b   Wu, Yih Ru ^a,b   Hsih, Mo Song ^a,b   Tu, Po Hsun ^a,b   Chang, Chen Nen ^a,b   Hsu, Chien Ning ^a,b   Wu, Tsu Lan ^a,b   Choon, Siew Eng ^f   Hsu, Chao Kai ^g   Chen, Der Yuan ^h   Liu, Chin San ⁱ   Lin, Ching Yuang ^j   Kaniwa, Nahoko ^k   Saito, Yoshiro ^k   Takahashi, Yukitoshi ^l   Nakamura, Ryosuke ^k   Azukizawa, Hiroaki ^m   Shi, Yongyong ⁿ   Wang, Tzu Hao ^a,b   Chuang, Shiow Shuh ^a,b   Tsai, Shih Feng ^o   Chang, Chee Jen ^a,b   Chang, Yu Sun ^p   Hung, Shuen Iu ^c   more..

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d MING CHUAN UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f HOSPITAL SULTANAH AMINAH   (Malaysia)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^j CHINA MEDICAL UNIVERSITY   (Taiwan)

^k NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^l SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^m OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ Shanghai GenomePilot Institutes for Genomics and Human Health   (China)

^o NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^p CHANG GUNG UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C; PHENYTOIN;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CYP2C GENE; DISEASE SEVERITY; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; JAPAN; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TAIWAN; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; EOSINOPHILIA; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; JAPAN; MALAYSIA; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENYTOIN; POLYMORPHISM, SINGLE NUCLEOTIDE; STEVENS-JOHNSON SYNDROME; TAIWAN; YOUNG ADULT;

EID: 84905901610     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.7859     Document Type: Article

References (40)

1. McCorry D, Chadwick D, Marson A. Current drug treatment of epilepsy in adults. Lancet Neurol. 2004;3(12):729-735. (Pubitemid 39535258)
2. Fields MC, Labovitz DL, French JA. Hospital-onset seizures: an inpatient study. JAMA Neurol. 2013;70(3):360-364.
3. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68(20):1701-1709. (Pubitemid 46763258)
4. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134-1138.
5. Yang CY, Dao RL, Lee TJ, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology. 2011;77(23):2025-2033.
6. Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf. 2012;11(5):767-778.
7. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609-611.
8. Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11(3):349-356.
9. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015-1018. (Pubitemid 46763406)
10. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087-2091.
11. Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D. Phenytoin-induced Stevens-Johnson syndrome with negative HLA-B*1502 allele in mainland China: two cases. Seizure. 2011;20(5):431-432.
12. Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307-1314.
13. Kuehn BM. FDA: epilepsy drugs may carry skin risks for Asians. JAMA. 2008;300(24):2845.
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. (Pubitemid 12149145)
15. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-68.
16. Tse KP, Su WH, Chang KP, et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet. 2009;85(2):194-203.
17. Ngow HA, Wan Khairina WM, Teh LK, et al. CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Singapore Med J. 2009;50(5):490-493.
18. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343-1350.
19. Thorn CF, Whirl-Carrillo M, Leeder JS, Klein TE, Altman RB. PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012;22(6):466-470.
20. Komatsu T, Yamazaki H, Asahi S, et al. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos. 2000;28(11):1361-1368.
21. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. 2000;10(2):95-104. (Pubitemid 30193071)
22. Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol. 2010;66(7):689-696.
23. Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol. 2011;18(9):1159-1164.
24. Niinuma Y, Saito T, Takahashi M, et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. 2014;14(2):107-114.
25. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47-56. (Pubitemid 14216359)
26. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529-2536.
27. Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy. 2013;43(11):1246-1255.
28. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349-355. (Pubitemid 32939439)
29. Nakamoto K, Kidd JR, Jenison RD, et al. Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. Pharmacogenet Genomics. 2007;17(2):103-114.
30. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-850. (Pubitemid 32385908)
31. Lee AY, Kim MJ, Chey WY, Choi J, Kim BG. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2004;60(3):155-159. (Pubitemid 38757125)
32. McCormack M, Urban TJ, Shianna KV, et al. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics. 2012;13(4):399-405.
33. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727-732. (Pubitemid 34215071)
34. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
35. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134-4139.
36. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006;16(4):297-306.
37. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134-1143.
38. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034-1041.
39. Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266-1276.
40. Wei CY, Chung WH, Huang HW, Chen YT, Hung SI. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012;129(6):1562-1569.